Neoadjuvant therapy (NAT) utilizing anti-HER2 drugs has become an important strategy for managing HER-2 positive BC patients because it can significantly improve the patients’ pathologic complete response (pCR), an important indicator reflecting treatment response and patient prognosis (3). Here, ERBB2 is linked to breast cancer.